Skip to main content
Clinical Trials/EUCTR2016-004806-32-IT
EUCTR2016-004806-32-IT
Active, not recruiting
Phase 1

Right ventriculAr reverse reModeling and hemodynamic improvement after add-on combination therapy (ambriSentan/PDE-5i) in PAH patientS (RAMSES) - RAMSES

ITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET0 sites54 target enrollmentMay 24, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
patients with pulmonary arterial hypertention
Sponsor
ITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET
Enrollment
54
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 24, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET

Eligibility Criteria

Inclusion Criteria

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 23
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 30

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials